5305-40-8

Basic information

• Product Name: 4,6-Dichloro-5-pyrimidinecarbaldehyde
• Synonyms: 4,6-DICHLOROPYRIMIDINE-5-CARBALDEHYDE,PURITY:97% MIN(HPLC);4,6-Dichloro-5-formylpyrimidine;4,6-Dichloro-5-pyrimidinecarbaldehyde ,96%;6-DichloropyriMidine-5-carboxaldehyde;5-PyriMidinecarbaldehyde, 4,6-dichloro-;5-PyriMidinecarboxaldehyde, 4,6-dichloro-;4,6-Dichloro-5-formylpyrimidine, 4,6-Dichloro-5-formyl-1,3-diazine;4,6-Dichloropyrimidine-5-carboxaldehyde,97%
• CAS NO: 5305-40-8
• Molecular Formula: C₅H₂Cl₂N₂O
• Molecular Weight: 176.99
• Product Categories: Pyrimidine;Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;Pyrimidines;PyrimidinesHeterocyclic Building Blocks;Heterocycle-Pyrimidine series;Pyrimidine series;Carbonyl Compounds;Heterocycles
• Mol File: 5305-40-8.mol
• Article Data: 47

Chemical Properties

• Melting Point: 70-72
• Boiling Point: 286.1 °C at 760mmHg
• Flash Point: 126.8 °C
• Appearance: White to off-white solid
• Density: 1.588 g/cm³
• Vapor Pressure: 8.65E-06mmHg at 25°C
• Refractive Index: 1.73
• Storage Temp.: 2-8°C
• PKA: -5.90±0.26(Predicted)
• CAS DataBase Reference: 4,6-Dichloro-5-pyrimidinecarbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-Dichloro-5-pyrimidinecarbaldehyde(5305-40-8)
• EPA Substance Registry System: 4,6-Dichloro-5-pyrimidinecarbaldehyde(5305-40-8)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-43-36/38-22
• Safety Statements: 26-36-36/37
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 5305-40-8(Hazardous Substances Data)

Usage

Chemical Properties

White to off-white solid

Uses

4,6-Dichloropyrimidine-5-carboxaldehyde is used as a substrate in the synthesis of N-terminal surrogate in amino acid and peptide analogues.

InChI:InChI=1/C13H12N2O/c1-10-5-4-8-13(15-10)14-9-11-6-2-3-7-12(11)16/h2-9H,1H3,(H,14,15)/b11-9-

Upstream product

• 1193-24-4 4,6-pyrimidinediol 
• 1193-21-1 4,6-dichloropyrimidine 
• 68-12-2 N,N-dimethyl-formamide 
• 14256-99-6 4,6-dihydroxy-5-formylpyrimidine 
• 1193-24-4 6-hydroxy-3,4-dihydropyrimidin-4-one 

Downstream Products

• 5305-44-2 4,6-dichloro-5-(1,3-dioxolan-2-yl)pyrimidine 
• 53736-87-1 4-chloro-6-(N-ethyl-anilino)-pyrimidine-5-carbaldehyde 
• 251989-01-2 4,6-bis[4-(tert-butyl)phenoxy]pyrimidine-5-carbaldehyde 
• 251989-02-3 4,6-bis[3,5-di(tert-butyl)phenoxy]pyrimidine-5-carbaldehyde 
• 251989-04-5 4,6-bis-(3-methyl-but-2-enylsulfanyl)-pyrimidine-5-carbaldehyde 
• 60025-05-0 4,6-dichloro-5-(α-hydroxyethyl)pyrimidine 
• 5399-92-8 4-chloro-1H-pyrazolo[3,4-d]pyrimidine 
• 35877-38-4 4-chloro-1-benzyl-1H-pyrazolo[3,4-d]pyrimidine 
• 1160701-79-0 4-chloro-6-{[4-(trifluoromethoxy)phenyl]amino}pyrimidine-5-carbaldehyde 
• 1328624-17-4 N-((2-(4-acetamido-6-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)pyrimidin-5-yl)oxazol-4-yl)methyl)acrylamide 
• 1328623-71-7 methyl 2-(4-amino-6-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)pyrimidin-5-yl)-4,5-dihydrooxazol-4-carboxylate 
• 1328623-72-8 methyl 2-(4-amino-6-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)pyrimidin-5-yl)oxazol-4-carboxylate 
• 1364411-02-8 (2-(4-amino-6-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)pyrimidin-5-yl)oxazol-4-yl)methanol 
• 1328623-74-0 5-(4-aminomethyloxazol-2-yl)-N⁽⁴⁾-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)pyrimidin-4,6-diamine 

Relevant articles and documents

Design, synthesis and evaluation of pyrrolo[2,3-d]pyrimidine-phenylamide hybrids as potent Janus kinase 2 inhibitors

Janus kinase 2 (JAK2) plays an essential role in the signaling of hormone-like cytokines and growth factors, which has been convinced as an important target of myeloproliferative neoplasms (MPNs) therapy. In this study, a series of novel pyrrolo[2,3-d]pyr

PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITOR

The present invention is related to processes for preparing ruxolitinib, or a salt thereof, and related synthetic intermediates related thereto.

1H-PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PLATINUM-RESISTANT CANCER

The invention relates to compounds of formula (I) and related compounds and their use in the treatment of cancer, especially platinum resistant cancer. The invention also provides a treatment comprising administration of a compound of formula (I) and a pl

HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSTION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT

The present invention relates to a heteroaryl derivative or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition for preventing or treating diseases associated with PI3 kinases, containing the same as an active ingredient. The heteroaryl derivative according to the present invention has an excellent effect of selectively inhibiting PI3 kinases, thereby being useful in preventing or treating PI3 kinase diseases such as: cancers, autoimmune diseases, and respiratory diseases.